Focus on epithelial ovarian cancer

Cancer Cell

Volumn 5, Issue 1, 2004, Pages 19-24

  Ozols, Robert F ^a   Bookman, Michael A ^a   Connolly, Denise C ^a   Daly, Mary B ^a   Godwin, Andrew K ^a   Schilder, Russell J ^a   Xu, Xiangxi ^a   Hamilton, Thomas C ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; ESTROGEN; ETOPOSIDE; GEFITINIB; GEMCITABINE; GESTAGEN; GONADOTROPIN; LAPATINIB; MONOCLONAL ANTIBODY; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PLATINUM; RETINOID DERIVATIVE; SEMAXANIB; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG;

ACNE; AGE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MODEL; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DIET; DNA REPAIR; DRUG TOXICITY; ENDOMETRIOSIS; EPITHELIUM CELL; ESTROGEN THERAPY; EXERCISE; EXPOSURE; FAMILY HISTORY; GENE MUTATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; HUMAN; INFLAMMATION; LIFESTYLE; LONG TERM EXPOSURE; MENOPAUSE; MUMPS; NONHUMAN; ONCOGENE K RAS; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; OVULATION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; RASH; REVIEW; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; VIRAL GENE THERAPY; X CHROMOSOME;

EID: 1642553649     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00002-9     Document Type: Review

References (40)

1. Ames B.N., Gold L.S., Willet W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. USA. 92:1995;5258-5265.
2. Barnes M.N., Grizzle W.E., Grubbs C.J., Partridge E.E. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J. Clin. 52:2002;216-225.
3. Baselga J. Why the epidermal growth factor receptor? The retionale for cancer therapy. Oncologist. 7:2002;2-8.
4. Bookman M.A. Developmental chemotherapy and management of recurrent ovarian cancer. J. Clin. Oncol. 21:2003;149s-167s.
5. Brown G.J., St. John D.J., Macrae F.A., Aittomaki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer. implications for gynecologic surveillance Gynecol. Oncol. 80:2001;346-349.
6. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W. Jr., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760.
7. Cramer D.W., Welch W.R. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 71:1983;717-721.
8. Dong Y., Hakimi M.A., Chen X., Kumaraswamy E., Cooch N.S., Godwin A.K., Shiekhattar R. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell. 12:2003;1087-1099.
9. Espey L.L. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol. Reprod. 50:1994;233-238.
10. Fathalla M.F. Incessant ovulation - a factor in ovarian neoplasia? Lancet. 17:1971;163.
11. Feeley K.M., Wells M. Precursor lesions of ovarian epithelial malingnancy. Histopathology. 38:2001;87-95.
12. Finkler N., Gordon A., Crozier M., Edwards R., Figueroa J., Garcia A., Hainsworth J., Irwin D., Silberman S., Allen L.et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 20:2001;208a.
13. Ganesan S., Silver D.P., Greenberg R.A., Avni D., Drapkin R., Miron A., Mok S.C., Randrianarison V., Brodie S., Salstrom J.et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 111:2002;393-405.
14. Godwin A.K., Testa J.R., Handel L.M., Liu Z., Vanderveer L.A., Tracey P.A., Hamilton T.C. Spontaneous transformation of rat ovarian surface epithelial cells. Association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer J. Natl. Cancer Inst. 84:1992;592-601.
15. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G.et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 297:2002;606-609.
16. Hu L., Hofmann J., Zaloudak C., Ferrara N., Hamilton T., Jaffe R.B. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol. 161:2002;1917-1924.
17. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53:2003;5-26.
18. King, M., Marks, J.H., and Mandell, J.B., for the New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646.
19. Lacey J.V. Jr., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., Schatzkin A., Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 288:2002;334-341.
20. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
21. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz S.L., Alvarez R.D., Kucera P.R., Small J.M. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 18:2000;106-115.
22. Narod S.A., Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr. Opin. Obstet. Gynecol. 14:2002;19-26.
23. Ness R.B., Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. 91:1999;1459-1467.
24. Ness R.B., Cottreau C. Response to. Possible role of ovarian epithelial inflammation in ovarian cancer J. Natl. Cancer Inst. 92:2000;163.
25. Nikitin A.Y., Connolly D.C., Hamilton T.C. Pathology of ovarian neoplasms in genetically modified mice. Comp. Med. in press:2004.
26. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 21:2003;3194-3200.
27. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
28. Prowse A., Frolov A., Godwin A.K. The genetics of ovarian cancer. Ozols R.F. American Cancer Society Atlas of Clinical Oncology. 2003;49-82 B.C. Decker Inc, Hamilton, Ontario.
29. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E.et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346:2002;1616-1622.
30. Riman T., Persson I., Nilsson S. Hormonal aspects of epithelial ovarian cancer. Review of epidemiological evidence Clin. Endocrinol. (Oxf.). 49:1998;695-707.
31. Roland I.H., Yang W.L., Yang D.H., Daly M.B., Ozols R.F., Hamilton T.C., Lynch H.T., Godwin A.K., Xu X.X. Loss of surface and cyst epithelial basement membranes and pre-neoplastic morphological changes in prophylactic oophorectomies. Cancer. 98:2003;2607-2623.
32. Sawiris G.P., Sherman-Baust C.A., Becker K.G., Cheadle C., Teichberg D., Morin P.J. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res. 62:2002;2923-2928.
33. Schilder R.J., Kohn E., Sill M.W., Lewandowski G., Lee R.B., Decesare S.L. Phase II trial of gefitinib in patients with recurrent ovarian or primary peritoneal cancer. Gynecology Oncology Group 170C Proc. Am. Soc. Clin. Oncol. 22:2003;451.
34. Schlosshauer P.W., Cohen C.J., Penault-Llorca F., Miranda C.R., Bignon Y.J., Dauplat J., Deligdisch L. Prophylactic oophorectomy. a morphologic and immunohistochemical study Cancer. 98:2003;2599-2606.
35. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje H., Mok S.C., D'Andrea A.D. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9:2003;568-574.
36. Testa J.R., Getts L.A., Salazar H., Liu Z., Handel L.M., Godwin A.K., Hamilton T.C. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 54:1994;2778-2784.
37. Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., Vermorken J.B., Torri V., Mangioni C., Pecorelli S.et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial. two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma J. Natl. Cancer Inst. 95:2003;105-112.
38. ICON (The International Collaborative Ovarian Neoplasm Group)Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer. The ICON3 randomized trial Lancet. 360:2002;505-515.
39. Verheul H.M.W., Hoekman K., Jorna A.S., Smit E.F., Pinedo H.M. Targeting vascular endothelial growth factor blockade. ascites and pleural effusion formation Oncologist. 5:2000;45-60.
40. Zeimet A.G., Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4:2003;415-422.